drugset / Trial / NCT01332721
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate safety and tolerability and determine a recommended Phase 2 dose for TRC105 when added to standard dose bevacizumab in patients with advanced solid tumors for which bevacizumab is indicated.
Timeline
- Start
- 2011-04
- Primary completion
- 2012-09
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carotuximab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | 15 mg/kg | — |
Indications
No indication recorded.